FIBROLAMELLAR HEPATOCELLULAR CARCINOMA

Clinical trials for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new FIBROLAMELLAR HEPATOCELLULAR CARCINOMA trials appear

Sign up with your email to follow new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug combo targets rare liver cancer in teens and adults

Disease control Recruiting now

This study is testing whether combining two drugs—DRP-104 and durvalumab—is safe and can shrink tumors in people with advanced fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer. It will enroll about 27 patients aged 12 and older whose cancer has progressed despite…

Matched conditions: FIBROLAMELLAR HEPATOCELLULAR CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control

Last updated Mar 25, 2026 14:08 UTC

FIBROLAMELLAR HEPATOCELLULAR CARCINOMA

Get alerted when new FIBROLAMELLAR HEPATOCELLULAR CARCINOMA trials appear

New drug combo targets rare liver cancer in teens and adults